Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin) - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Long-Term Efficacy and Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis Patients: Results from a Three-Year Extension Study (ADjoin)

  • By

  • Emma Guttman-Yassky

  • Alan D. Irvine

  • Melinda Gooderham

  • Stephan Weidinger

  • Lynda Spelman

  • Jonathan I. Silverberg

  • Heidi Crane

  • Hany ElMaraghy

  • Louise DeLuca-Carter

  • Maria Lucia Buziqui Piruzeli

  • Georgia Martimianaki

  • Evangeline Pierce

  • Helena Agell

  • Diamant Thaçi

  • June 19, 2026

Share

Original Source(s)

Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)

  • by Emma Guttman-Yassky, Alan D. Irvine, Melinda Gooderham, Stephan Weidinger, Lynda Spelman, Jonathan I. Silverberg, Heidi Crane, Hany ElMaraghy, Louise DeLuca-Carter, Maria Lucia Buziqui Piruzeli, Georgia Martimianaki, Evangeline Pierce, Helena Agell, Diamant Thaçi

  • June 19, 2026

Related Content

Psoriasis–AD Switching May Mimic Treatment Failure

Recognizing sustained switches between the two diseases can prevent premature discontinuation of effective biologics and point toward Janus kinase inhibitors, a 148-patient cohort suggests.

Evaluating Itch in Atopic Dermatitis: Perspectives from UK Dermatologists Through a Cross-Sectional Survey and Narrative Review

Case Report: Ivarmacitinib in the treatment of refractory primary cutaneous amyloidosis